Landscape of the Chinese Domestic Endoscopy Industry

Market Value 2.3 Billion Yuan: Domestic Endoscopy Industry Enterprise Lists on Beijing Stock Exchange!

It is well known that in recent years, global population aging, the increasing adoption of minimally invasive surgeries, and accelerated technological innovation have driven continuous expansion of the medical endoscopy market. The Chinese market, bolstered by policy support, accelerated domestic substitution, and the release of demand in primary healthcare, has demonstrated a growth trend far exceeding the global average.

According to industry estimates, the global medical endoscopy equipment market reached $32.98 billion in 2025. It is projected to grow to $35.2 billion in 2026 and exceed $62 billion by 2035, with a compound annual growth rate (CAGR) of approximately 6.5% from 2026 to 2035. Growth is primarily driven by the popularity of minimally invasive surgeries, increased demand for early disease screening, and product iteration driven by technological advancements.

On March 27, Promisemed, a player in the endoscopy market, was officially listed on the Beijing Stock Exchange, achieving a market value of 2.3 billion yuan. Over the past three years, the company has maintained consistent profitability, with cumulative net profits exceeding 150 million yuan!

Additionally, the company plans to raise nearly 400 million yuan through this listing, primarily for projects in puncture intervention, minimally invasive intervention, and other medical device sectors.

Unit: Ten thousand RMB

The company emphasizes the increasing importance of minimally invasive interventional medical devices, particularly single-use minimally invasive intervention products. This industry is currently in a phase of rapid development, with numerous unmet clinical needs and significant opportunities for iterative upgrades of existing products.

Data shows that the global minimally invasive surgery market (including rigid endoscopes, MIS equipment, and MISIA) was approximately $29.87 billion in 2023. This figure is expected to rise to $34.84 billion by 2025, with a CAGR of 8%, making it one of the strongest growth segments within the global medical device market.

Promisemed Officially Lists: Endoscopy Market Size Continues to Surge!

According to Promisemed, endoscopic technology is primarily divided into endoscopy and laparoscopy/thoracoscopy. Endoscopic diagnosis and treatment involve using an endoscope to examine and treat diseases. By inserting an endoscope through natural body orifices, physicians can observe pathological changes within the digestive or respiratory tracts, including ulcers, tumors, polyps, and inflammation. Through techniques such as tunnel endoscopy, minimally invasive treatment can even be performed on tissues outside natural orifices.

Various minimally invasive diagnostic and therapeutic instruments are used in conjunction with endoscopes, complementing each other. They are commonly employed in diagnosing and treating digestive tract diseases such as peptic ulcers, gastrointestinal bleeding, biliary tract diseases, liver diseases, and pancreatic diseases. Additionally, departments such as pulmonology, otorhinolaryngology, and urology also utilize these techniques. Laparoscopy/thoracoscopy primarily enters sterile body cavities through surgical incisions in sterile environments, encompassing techniques like laparoscopy, thoracoscopy, and arthroscopy.

The company emphasizes that in the field of endoscopic diagnosis and treatment, traditional endoscope products are primarily reusable. These products are often expensive and carry risks of cross-infection due to potential inadequate disinfection. Promisemed‘s focus in endoscopic intervention products lies in single-use endoscopic intervention products, which can effectively address the aforementioned issues associated with reusable products. This segment belongs to an emerging medical device sub-industry with promising future development prospects.

According to Boston Scientific forecasts, the global market size for endoscopic therapeutic devices was $6.0 billion in 2023, with an expected average annual growth rate of 7% from 2024 to 2026.

In recent years, China has experienced accelerated population aging, with the elderly demographic demanding greater medical examination and treatment. Concurrently, as living standards improve, public awareness of disease screening has increased, expanding the demand for preventive examinations. Moreover, ongoing healthcare system reforms in China are progressively improving the medical and health system, enabling primary healthcare institutions to acquire endoscopic equipment.

Therefore, long-term demographic shifts, rising incidence of malignant tumors, the popularity of minimally invasive diagnosis and treatment, increased endoscopy utilization and treatment rates (penetration), and higher domestic substitution rates are all driving continuous growth in the Chinese endoscopic diagnostic and therapeutic device market.

According to sources like CNKI, the domestic medical endoscope market was valued at 22.24 billion yuan in 2022, with endoscopic consumables accounting for 5 billion yuan. It is projected that by 2030 (assuming no centralized procurement impact), the domestic medical endoscope market will reach 48.74 billion yuan, with endoscopic consumables reaching 14.92 billion yuan.

Among endoscopic intervention products, single-use devices, which eliminate the need for disinfection and effectively avoid cross-infection risks, are expected to become a significant segment of the endoscopic intervention market with favorable development prospects.

Recognizing the immense market potential and clinical value of single-use endoscope products, Promisemed quickly entered the field of single-use endoscopic medical devices and consumables. The company has invested heavily in developing products such as electronic endoscope image processors, single-use bronchial visualization catheters, single-use electronic cholangioscopes, and various cavity intervention consumables.

The company’s single-use biopsy forceps, designed for rapid acquisition of suspicious tissue samples under endoscopy while minimizing bleeding and damage to the endoscope, were launched in late 2023. A single-use endoscopic injection needle, featuring a unique inner tube design and beveled needle tip to ensure optimal puncture force and flow rate, along with a safety lock to prevent accidental needle advancement that could damage the endoscope, was launched in 2024.

Additionally, a single-use electrosurgical snare, featuring a braided loop design for enhanced coagulation and 360-degree rotation for polyp resection, was also launched in 2024. The company’s pipeline for endoscopic intervention products is extensive and covers a broad spectrum, aiming to provide downstream medical institutions with comprehensive solutions for single-use endoscopic products, ultimately better serving patients and healthcare professionals.

From the perspective of endoscope products, global medical endoscopy technology is rapidly evolving towards higher definition, intelligence, minimally invasive applications, and single-use configurations, driving continuous product performance upgrades and expanding clinical application boundaries.

High-definition imaging technology is becoming ubiquitous. 4K ultra-high-definition endoscopes have become the mainstream procurement choice for tertiary hospitals globally, offering resolution exceeding 2000 lines and 100% color fidelity compared to traditional products. This enables clear visualization of microscopic lesion structures, increasing the detection rate of early lesions by 25%. 8K resolution endoscopes are increasingly penetrating the high-end market, primarily used in high-precision surgical scenarios like neurosurgery and thoracic surgery.

Furthermore, the integration of AI technology with endoscopes is deepening, becoming a core direction for industry innovation. In 2026, the installation rate of AI-assisted diagnostic modules in medical endoscopes reached 47%. Utilizing deep learning algorithms, these modules enable automatic lesion annotation and grading diagnosis, achieving diagnostic accuracy as high as 96.7%. This represents a 40% increase in efficiency compared to manual diagnosis, while potentially reducing medical costs by 12%-15% and shortening patient hospital stays by 1.8 days, demonstrating significant value for promotion in primary healthcare institutions.

High-Speed Development of the Global Medical Device Market: Domestic Market Growth Far Exceeds Overseas!

From the perspective of the medical device market, global demand has been steadily growing in recent years due to increasing population aging. According to Statista, the global medical device market was valued at $566.2 billion in 2023 and is projected to reach $772.5 billion by 2029, with a CAGR of 5.3%.

Driven by both policy support and medical demand, the Chinese medical device market has maintained steady growth. According to the “China Medical Device Industry Blue Book (2024),” the market size of China’s medical device industry reached 1.0328 trillion yuan in 2023, with a five-year CAGR of approximately 13.43%. Preliminary estimates suggest the market size will reach 1.1103 trillion yuan in 2024.

It is worth noting that low-value medical consumables refer to single-use medical materials commonly used during medical services that have relatively low value. Based on specific applications, they can be categorized into medical sanitary materials and dressings, infusion and puncture products, medical polymer materials, medical disinfection products, anesthesia consumables, operating room consumables, and medical technology consumables. The company’s main products fall under the infusion and puncture category within the low-value medical consumables industry.

As single-use materials, low-value medical consumables enhance the safety of examinations and treatments and prevent disease transmission between healthcare providers and patients caused by shared medical devices. With increasing requirements for medical hygiene, their importance in medical services is steadily rising.

According to the “China Medical Device Blue Book (2024)” and China Business Industry Research Center statistics, the global low-value medical consumables market is substantial and demonstrates steady growth, reaching $72.2 billion in 2023.

Driven by adjustments in China’s pharmaceutical and medical device consumption structure, improvements in medical conditions, increased medical insurance coverage, and enhanced resident payment capacity, the domestic low-value medical consumables industry is developing steadily, presenting broad market prospects.

According to the “China Medical Device Industry Blue Book (2024)” and China Business Industry Research Center estimates, the domestic low-value medical consumables market reached 128 billion yuan in 2023.

Furthermore, infusion and puncture devices represent a crucial sub-category within low-value medical consumables. These devices typically use a puncture needle or injection needle to penetrate the body for purposes such as blood transfusion, fluid infusion, anesthesia, angiography, blood sampling for tests, etc. According to China Business Industry Research Center, the Chinese market size for medical infusion and puncture devices was 33.16 billion yuan in 2022 and is projected to reach 52.31 billion yuan by 2026.

From the perspective of the endoscope market, the global medical endoscopy industry is in a mature phase of steady growth. Technological innovation, the popularity of minimally invasive surgery, and population aging are the core drivers of industry growth. The regional market exhibits a pattern characterized by “Asia-Pacific leading, Europe and North America mature.” International giants dominate the market, while emerging enterprises are gradually rising.

Benefiting from multiple favorable factors such as policy support, accelerated domestic substitution, and the release of demand from primary healthcare, the Chinese medical endoscopy market is demonstrating high-speed growth, with market size growth rates leading globally. The competitiveness of domestic enterprises is continuously improving, gradually breaking the import monopoly.

Although the global and Chinese medical endoscopy industries still face challenges such as core technology bottlenecks, insufficient enterprise competitiveness, and uneven distribution of medical resources, the industry’s future development prospects are broad, driven by continued technological innovation, strengthening policy support, and sustained market demand.

The global market will continue to advance towards higher-end, intelligent, and single-use directions. Driven by domestic substitution, expansion into primary healthcare, and global expansion, the Chinese market is poised to achieve high-quality development, gradually transitioning from a “major endoscope-producing nation” to an “innovation powerhouse,” contributing Chinese strength to the development of the global medical endoscopy industry.

Witnessing the rapid growth of China’s endoscopy market, we at ZRHmed — as a supplier of endoscopic accessories — are proud to be part of this momentum and are committed to growing the market together, even alongside our competitor, Pioneer.

We, Jiangxi Zhuoruihua Medical Instrument Co.,Ltd., is a manufacturer in China specializing in the endoscopic consumables, include Endotherapy Series such as biopsy forceps, hemoclip, polyp snare, sclerotherapy needle, spray catheter, cytology brushes, guidewire, stone retrieval basket, nasal biliary drainage cathete etc. which are widely used in EMR, ESD, ERCP.

Our products are CE certified and with FDA 510K approval, and our plants are ISO certified. Our goods have been exported to Europe, North America, Middle East and part of Asia, and widely obtains the customer of the recognition and praise!